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Abstract
Purpose We investigated the association between serum
levels of 25-hydroxyvitamin D (25-OHD) and risk of death
in Norwegian cancer patients.
Methods The study population was 658 patients with
cancers of the breast (n = 251), colon (n = 52), lung
(n = 210), and lymphoma (n = 145), obtained from
JANUS, a population-based serum bank in Norway. Serum
samples were collected within 90 days of cancer diagnosis
and were analyzed for 25-OHD. Patients were diagnosed
during 1984–2004 and were followed for death throughout
2008. We used Cox regression models to assess the rela-
tionship between serum 25-OHD and risk of death.
Results Three hundred and ninety-nine patients died
during follow-up, of whom 343 (86%) died from cancer.
Adjusted for sex, age at diagnosis, and season of blood
sampling, patients with 25-OHD levels below 46 nmol/L at
diagnosis experienced shorter survival. Compared to
patients in the lowest quartile of serum 25-OHD, the risk of
cancer death among patients in the highest quartile was
signiﬁcantly reduced (HR 0.36 95% CI 0.27, 0.51). The
estimated change in risk of cancer death was most pro-
nounced between the ﬁrst and the second quartile. The
associations between 25-OHD levels and survival were
observed for all four cancers.
Conclusions Higher circulating serum levels of 25-OHD
were positively associated with the survival for cancers of
the breast, colon, lung, and lymphoma.
Keywords Serum  Vitamin D  Survival 
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Introduction
Vitamin D is increasingly recognized as an important,
modiﬁable factor in the natural history of several cancers.
Vitamin D synthesis begins when sunlight converts
7-dehydrocholesterol in the skin to vitamin D3 [cholecal-
ciferol]. Vitamin D3 and/or vitamin D2 [ergocalciferol] can
also be obtained from the diet. The liver hydroxylates
vitamin D3 to form 25-hydroxyvitamin D (25-OHD), the
storage form of vitamin D, and the accepted measure of an
individual’s vitamin D status [1]. The active form of
vitamin D results from a second hydroxylation of 25-OHD
in the 1-a position to form 1a,25-Dihydroxyvitamin D
(1,25(OH)2D). Although the ‘‘classic’’ site of 1,25(OH)2D
synthesis is the kidney, many non-renal tissues, including
the prostate, colon, and breast, express 1-a hydroxylase
(CYP27B1) and synthesize 1,25(OH)2D from 25-OHD in
an autocrine fashion [1]. Unlike the kidney, where the
hydroxylation of 25-OHD is tightly regulated, the
hydroxylation of 25-OHD in non-renal organs appears to
be substrate dependent, suggesting why the non-classical
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of 25-OHD [2, 3].
In Norway, a country where serum vitamin D levels
vary markedly between summer and winter, a 15–25%
lower risk of dying from breast, colon, and prostate cancer
was reported for patients diagnosed during summer or fall,
when vitamin D levels are typically higher, compared to
patients diagnosed during the winter [4]. Similar results
were observed for Norwegian patients with lymphoma [5]
and lung cancer [6]. However, an important limitation of
these studies is that they are ecologic, i.e., they are based
on data at the level of the population rather than individual.
More recently, the association between vitamin D and
cancer survival has been investigated using individual
serum levels of 25-OHD, the accepted measure of an
individual’s vitamin D status [7]. Positive associations
between serum 25-OHD and survival have been reported
for studies including colorectal [8, 9], breast [10], and
prostate cancer [11] and for non-Hodgkin’s lymphoma [12]
and chronic lymphocytic leukemia [13]. Although many
studies report a positive association between 25-OHD and
survival, it is possible that this association, at least in part,
reﬂects an inﬂuence of advanced cancer on serum 25-OHD
levels rather than a beneﬁcial effect of serum 25-OHD
levels on survival. For example, Palmieri et al. [14]
reported signiﬁcantly higher serum levels of 25-OHD in
early than in later-stage breast cancers. These ﬁndings
emphasize the need to address potential confounding by
disease stage in the studies of vitamin D and survival.
The present study examined the relationship between
serum levels of 25-OHD and the risk of death in Norwe-
gian patients with breast cancer, colon cancer, lung cancer,
and lymphoma, using individual serum samples collected
at the time of diagnosis. Results were examined controlling
for disease stage, as provided by clinical information in the
cancer registry. These four cancers were selected a priori,
based on positive results observed for survival from these
cancers in ecologic studies in Norway.
Materials and methods
Patients and serum samples
The JANUS serum bank, established in 1973, includes
serum samples from more than 330,000 healthy donors, of
whom 91% were recruited from population-based health
examinations of participants in the 35–49 year age-group.
The health examinations were performed in several Nor-
wegian counties during 1973–2005 and had an attendance
rate of 88 percent. The remainder of the JANUS cohort
(9%) consists of Red Cross blood donors (http://www.
kreftregisteret.no/en/Research/Janus-Serum-Bank/). Examinees
and donors who subsequently developed cancer and were
admitted to the Norwegian Radium hospital for the treat-
ment donated an additional serum sample to JANUS at the
time of diagnosis. In the present study, this last sample was
used for 658 white patients. The cancer types studied were
as follows: breast (n = 251), colon (n = 52), lung
(n = 210), and lymphoma (n = 145). All patients were
diagnosed during the period 1973–2007. All cancers were
veriﬁed pathologically, by histology and/or cytology, as
appropriate. Four percent of the patients were diagnosed
and treated in the 1970s, 17% in the 1980s, 31% in the
1990s, and 48% during 2001–2007. The serum samples
were collected within 90 days of cancer diagnosis. Patients
who were not alive 30 days after the date of serum col-
lection were excluded. Seventy-ﬁve ll of serum was drawn
from each patient’s sample for analysis of 25-OHD, which
was performed using a competitive radioimmunoassay
(RIA) (DiaSorin, Stillwater, MN). All the serum samples
were analyzed at the same time in August 2009 (total
coefﬁcient of variation was 12%). Before any statistical
analyses were performed, patients were categorized
according to quartiles of 25-OHD for the total group of
cancer patients: \46, 46–61, 62–81, or [81 nmol/L. In a
sub-analysis, the quartiles were deﬁned for each speciﬁc
type of cancer.
A linkage between the Cancer Registry of Norway and
the JANUS serum bank was made via the unique personal
identiﬁcation number (PIN) that identiﬁes each Norwegian
citizen [15]. Information about the cancer, date of birth,
and sex was retrieved from the population-based Cancer
Registry. Data on cause of death were obtained from the
National Death Registry. The underlying cause, stated on
the death certiﬁcate, was used. The codes for stage of
disease at the time of diagnosis have been changed during
the 20 years of patient inclusion into this study. Therefore,
a re-coding was performed on the bases of clinical and
pathological information about the patients in the Cancer
Registry by an experienced medical coder. Cancer stage at
the time of diagnosis was coded as: local, regional
metastasis, distant metastasis, and unknown. The patients’
25-OHD serum level was unknown to the coder. Season of
blood sampling was deﬁned as Winter: December–Febru-
ary; Spring: March–May; Summer: June–August, or Fall:
September–November.
Statistical analyses
The patients were followed from the date of diagnosis until
date of death, migration, or the end of follow-up (31
December 2008), whichever occurred ﬁrst. Cox propor-
tional hazard regression models were used to assess the
relationship between serum 25-OHD and the risk of death
of cancer-speciﬁc mortality and overall mortality (all
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123causes). Hazard rates of death (HR) were estimated
adjusting for sex, age, and season of blood sampling.
Additional stratiﬁed analyses were conducted within dis-
ease stage. Kaplan–Meier survival curves with log-rank
tests were used to illustrate the cumulative survival by
follow-up time. All statistical analyses were conducted
using SPSS [16].
Results
Table 1 presents the sex distribution, median age at diag-
nosis, and median time between 25-OHD measurement and
diagnosis. The study population was relatively young, with
a median age of 56.5 years at the time of cancer diagnosis.
The median time between diagnosis and measurement of
serum 25-OHD was 37 days (Inter-quartile range;
20–56 days). A regression analysis of the association
between calendar year of diagnosis and 25-OHD level
showed a weak downward trend during 1973–2007 of
0.07 nmol/L per year.
During the follow-up period, 399 patients died, of whom
343 (86%) from cancer. This proportion of deaths from
cancer is in accordance with the expected proportion based
on death rates from the total Norwegian population (85%),
when cancer type, age at diagnosis, sex, and time of fol-
low-up are taken into account.
Cancer-speciﬁc mortality
Table 2 (Model I) shows the hazard ratio of dying from
cancer among patients with breast, colon, lung, and lym-
phoma by quartile of serum 25-OHD. A signiﬁcantly
poorer prognosis is seen for patients with 25-OHD levels
below 46 nmol/L at diagnosis. The association between
25-OHD and death rate, adjusted for sex, age at diagnosis,
and season of blood sampling, is shown in Model II. Both
age at diagnosis and sex were signiﬁcantly associated with
prognosis, but the adjustment did not materially inﬂuence
the association between 25-OHD and prognosis.
Model III shows the results when adding the variables,
stage of disease at the time of diagnosis and time between
serum sampling and 25-OHD measurement to the adjust-
ment list. The adjustments did not change the hazard ratios.
Table 3A shows the association between quartiles of
serum 25-OHD and risk of cancer-speciﬁc death for each
type of cancer, adjusted for sex, age at diagnosis, and
season of blood sampling. Although survival times differ
markedly among the four cancers, a similar pattern exists
for all the cancers, with a poorer prognosis for the lowest
25-OHD level. A further adjustment for stage of disease
revealed estimates that deviate only minimally from what
is presented for breast and lung cancer. The colon cancer
group consists of 52 patients only, and a non-signiﬁcant
trend was suggested both before and after adjustment for
stage (data not shown).
Since the quartiles for all four types of cancer combined
differ from the quartiles deﬁned for each speciﬁc type of
cancer, an additional analysis was carried out. Table 3B
shows the hazard ratios for each type of cancer, using
cancer-speciﬁc quartile groups. The results were, however,
similar.
The Kaplan–Meier plots in Fig. 1 demonstrate that
25-OHD levels are associated with substantial differences
in length of survival. For example, for lung cancer, the
estimated median survival is 5.3 months (95% CI 3.1, 7.5)
in the lowest quartile of 25-OHD and 22.6 months (95% CI
15.6, 29.6) in the highest quartile.
Information about disease stage at the time of diagnosis
was available for breast, colon, and lung cancer. Table 4
shows the risk of dying from cancer stratiﬁed by disease
stage.
Because some patients might have received treatment
before their blood draw, we examined the possibility that
treatment could inﬂuence the vitamin D levels. We repe-
ated the analyses in Tables 2, 3, 4, and 5 adding an indi-
cator for blood draw before or after the day of diagnosis.
The results were unchanged (data not shown).
Overall mortality
Among the 658 patients included in the study, only 56 died
from causes other than the types of cancer under study.
Results from analyses performed with all-cause mortality
as the endpoint are shown in Table 5, which revealed
similar results as for cancer-speciﬁc death (see Table 3A).
Table 1 Characteristics of the cancer patients at the time of
diagnosis
Characteristics Breast Colon Lung Lymphoma Total
Number
Female/male 251/0 20/32 78/132 52/93 401/257
Age (years)
Median 53.6 59.1 59.0 56.3 56.5
Range (36–75) (32–75) (42–82) (37–79) (32–82)
Days between serum collection and diagnosis*
Median 33.0 30.5 45.0 41.0 37.0
Range (-85, 90) (-82, 87) (-86, 90) (-90, 88) (-90, 90)
Stage, number
Local 67 9 24
Regional 74 17 82
Distant 24 24 94
Unknown 86 2 9
* Negative value means before and positive means after diagnosis
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We observed strong positive associations between serum
levels of 25-OHD and prognosis for this young group of
patients diagnosed with cancers of the breast, colon, lung,
and lymphoma. For all cancers combined, the risk of dying
during follow-up among patients in the highest quartile of
25-OHD was 36% (95% CI, 26%, 49%) of the risk
observed among patients in the lowest quartile.
The relationship between serum 25-OHD levels and
cancer survival has been examined in several studies,
including our own [17]. The present analyses extend our
previous ﬁndings on patients with prostate cancer. Our
ﬁndings for the four cancer types are consistent with those
of several recent reports. For example, Ng and colleagues
[8] studied the relationship between 25-OHD levels and
survival in 304 patients with colorectal cancer. They
observed a signiﬁcantly decreased hazard ratio (HR 0.52,
Table 2 Hazard ratio (HR) and 95% conﬁdence intervals (95% CI) of dying from cancer in patients with cancer of breast, colon, prostate, or
lymphoma, in quartile groups of serum 25-OHD
Model I Model II** Model III***
HR (95% CI) HR (95% CI) HR (95% CI)
1. Quartile (\46 nmol/L)
109/161*
1.00 Reference 1.00 Reference 1.00 Reference
2. Quartile (46–61 nmol/L)
93/170*
0.58 (0.44, 0.77) 0.66 (0.50, 0.87) 0.70 (0.51, 0.94)
3. Quartile (62–81 nmol/L)
75/162*
0.45 (0.34, 0.61) 0.46 (0.34, 0.62) 0.46 (0.34, 0.62)
4. Quartile ([81 nmol/L)
66/165*
0.35 (0.35, 0.48) 0.36 (0.26, 0.50) 0.36 (0.25, 0.49)
p for trend p\0.01 p\0.01 p\0.01
* Number of fatal cases/number of patients
** Adjusted for sex, age at diagnosis and season of blood sampling
*** Adjusted for sex, age at diagnosis, season of blood sampling, time between serum sampling and 25-OHD measurement, and stage of the
disease at the time of diagnosis
Table 3 Hazard ratio (HR) and
95% conﬁdence intervals (95%
CI) of dying from the actual
cancer disease by quartile
groups of 25-OHD for all cancer
patients combined (A) and by
cancer-speciﬁc quartile groups
of 25-OHD (B)
* Number of fatal cases/
Number of patients
** Adjusted for sex, age at
diagnosis and season of blood
sampling
*** Quartile limits: Breast 50,
67, 86 nmol/L; Colon 44, 56,
77 nmol/L; Lung 41, 56,
76 nmol/L; Lymphoma 44, 60,
77 nmol/L
Breast Colon Lung Lymphoma
HR (95% CI)** HR (95% CI)** HR (95% CI)** HR (95% CI)**
(A)
1. Quartile
(\46 nmol/L)
1.00 reference
22/45*
1.00 reference
8/13*
1.00 reference
59/63*
1.00 reference
20/40*
2. Quartile
(46–61 nmol/L)
0.60 (0.33, 1.09)
22/62*
0.53 (0.17, 1.64)
6/12*
0.39 (0.26, 0.58)
49/62*
0.61 (0.31, 1.20)
16/34*
3. Quartile
(62–81 nmol/L)
0.43 (0.22, 0.82)
16/58*
0.60 (0.20, 1.79)
8/17*
0.34 (0.22, 0.53)
36/44*
0.44 (0.22, 0.88)
15/43*
4. Quartile
([81 nmol/L)
0.41 (0.22, 0.78)
22/86*
0.37 (0.08, 1.81)
4/10*
0.18 (0.11, 0.29)
29/41*
0.38 (0.17, 0.83)
11/28*
p for trend p = 0.01 p = 0.27 p\0.01 p = 0.02
(B)
1. Quartile*** 1.00 reference
22/45*
1.00 reference
8/13*
1.00 reference
59/63*
1.00 reference
20/40*
2. Quartile*** 0.47 (0.26, 0.85)
22/62*
0.46 (0.15, 1.48)
6/12*
0.37 (0.24, 0.57)
49/62*
0.71 (0.36, 1.40)
16/34*
3. Quartile*** 0.53 (0.29, 0.95)
16/58*
0.73 (0.25, 2.15)
8/17*
0.35 (0.23, 0.54)
36/44*
0.45 (0.21, 0.94)
15/43*
4. Quartile*** 0.42 (0.21, 0.82)
22/86*
0.20 (0.04, 1.10)
4/10*
0.18 (0.11, 0.29)
29/41*
0.39 (0.18, 0.83)
11/28*
p for trend p = 0.01 p = 0.16 p\0.01 p = 0.01
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12395% CI, 0.29, 0.94) for overall survival when patients in
the highest quartile of 25-OHD were compared with
patients in the lowest quartile. A non-signiﬁcant trend
toward improved colorectal cancer-speciﬁc mortality also
was seen. The average interval between blood draw and
cancer diagnosis in that study was 6 years.
Two studies have investigated the association between
circulating 25-OHD levels, measured at the time of diag-
nosis, and prognosis in patients with non-small cell lung
cancer, one in early-stage patients and the other in patients
with advanced disease [18, 19]. A positive association
between 25-OHD levels and survival was suggested for
patients with early-stage disease, whereas no clear
association was demonstrated for advanced stages. In a
study of 512 early-stage breast cancer cases by Goodwin
et al. [10], women with vitamin D levels\50 nmol/L had a
signiﬁcantly increased risk of distant recurrence and death
compared to women with 25-OHD levels C50 nmol/L.
Our result for all types of lymphoma combined is
comparable with the results for the solid tumors studied
and is consistent with the results for two studies by Drake
et al. [12] and Shanafelt et al. [13], respectively. These
authors deﬁned insufﬁcient vitamin D status as 25-OHD
levels\62.5 nmol/L and found a poorer prognosis for this
group among patients with non-Hodgkin’s lymphoma and
chronic lymphocytic leukemia.
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Fig. 1 The cumulative survival curves for quartile groups of serum 25-OHD, for patients with cancer of breast, colon, lung, and lymphoma
Table 4 Hazard ratio (HR) and
95% conﬁdence intervals (95%
CI) of dying from the actual
disease in breast, colon, and
lung cancer patients stratiﬁed by
stage of disease at the time of
diagnosis, in quartile groups of
25-OHD
* Number of fatal cases/
Number of patients
** Adjusted for sex, age at
diagnosis, and season of blood
sampling
Localized Regional Distant Unknown
HR (95% CI)** HR (95% CI)** HR (95% CI)** HR (95% CI)**
1. Quartile
(\46 nmol/L)
1.00 reference
4/12*
1.00 reference
31/43*
1.00 reference
43/49*
1.00 reference
11/17*
2. Quartile
(46–61 nmol/L)
0.39 (0.10, 1.59)
8/29*
0.48 (0.27, 0.83)
23/46*
0.73 (0.45, 1.20)
31/35*
0.69 (0.30, 1.58)
15/26*
3. Quartile
(62–81 nmol/L)
0.34 (0.09, 1.36) 6/24* 0.39 (0.22, 0.71)
20/36*
0.39 (0.23, 0.66)
25/33*
0.42 (0.16, 1.05)
9/26*
4. Quartile
([81 nmol/L)
0.15 (0.03, 0.89)
4/35*
0.29 (0.15, 0.53)
20/49*
0.38 (0.22, 0.66)
20/25*
0.39 (0.16, 0.98)
11/28*
p for trend p = 0.06 p\0.01 p\0.01 p = 0.04
Cancer Causes Control (2012) 23:363–370 367
123It is important to distinguish studies of serum vitamin D
and cancer survival from studies of serum vitamin D and
cancer incidence and/or cancer mortality in populations.
With the exception of studies of colorectal cancer, where
prospective incidence/mortality studies have generally
shown protective effect of serum 25-OHD, most studies of
serum 25-OHD and the risk of cancer have not shown
convincing evidence of risk reduction and some have
shown apparent increases in cancer risk [20]. One expla-
nation for the discrepancy in the results of these studies
concerns the effects of vitamin D on different stages in the
carcinogenic process. Laboratory studies have convinc-
ingly shown effects of the hormonal form of vitamin D on
cancer promotion and progression [21]. However, few data
are available on the possible effects of vitamin D on cancer
initiation (i.e., the initial events in causing cell transfor-
mation from normal to malignant phenotype). Thus, it is
conceivable that vitamin D does not affect cancer initiation
and therefore does not inﬂuence epidemiologic studies of
cancer incidence. Conversely, the established effects of
vitamin D on tumor promotion may underlie the positive
associations observed in epidemiologic studies of cancer
survival.
There are several possible explanations for the observed
associations between higher serum levels of 25-OHD and
improved cancer survival. These include chance, selection
bias, confounding, effect of the cancer on 25-OHD levels
(‘‘reverse causality’’), and effect of serum 25-OHD levels
on survival. The sample size, and the similar association
pattern observed for the four cancer types examined, makes
chance an unlikely explanation. Because our sample is
population-based with no loss to follow-up, selection bias
can largely be excluded. We do not have information about
lifestyle factors that are correlated to 25-OHD and that
might inﬂuence survival (see Jacobs et al. [22]). Obvious
factors, in particular for breast and colon cancer, would be
physical activity and body mass index (BMI). In the breast
cancer study by Goodwin et al. [10], information about
BMI was included in the analyses. The results did not show
any essential inﬂuence on the strength of the association
between 25-OHD and prognosis. Even when adjusting for
strong prognostic factors for breast cancer and some
treatment information, only a limited attenuation was seen.
Ng et al. [8] included information on BMI and post-diag-
nostic physical activity in their colorectal study, but no
strong inﬂuence on the association between 25-OHD and
survival was observed.
It has been suggested that genetic factors may account
for a substantial proportion of the variability in serum
25-OHD [23, 24], and thus genetics could confound an
association between serum 25-OHD and survival. How-
ever, the same genetic factors then need to be causally
linked to the case fatality of the cancer. Because the
positive associations between 25-OHD and cancer survival
seen in the present study are strong, the association
between a potential confounder and 25-OHD and the
association between the potential confounder and the can-
cer survival rate must also be strong [25]. Thus far, studies
on the heritability of vitamin D have not provided sufﬁcient
information to permit conclusions about the role of genetic
factors in cancer survival [24].
An effect of cancer lowering the serum level of 25-OHD
(‘‘reverse causality’’) is possible. In line with studies sug-
gesting lower vitamin D levels among hospitalized or
elderly persons, we may hypothesize that cancer also may
inﬂuence the serum level of 25-OHD (see Bandeira et al.
[26]). We consider that reverse causality is unlikely to be a
major explanation for our ﬁndings for several reasons.
First, patients with less than 1 month of survival after
blood draw, for whom low levels of 25-OHD could reﬂect
poor health, were excluded. In addition, we conducted
additional analyses in which patients with less than 2 and
less than 3 months of survival time were excluded. The
association between 25-OHD quartiles and prognosis was
almost unchanged (data not shown). Second, for diseases
like breast cancer, the functional status at the time of
diagnosis is often unimpaired, and the mean survival is
relatively long. Moreover, as shown in Table 4, positive
Table 5 Hazard ratio (HR) and
95% conﬁdence intervals (95%
CI) of dying from all causes, in
cancer-speciﬁc quartile groups
of 25-OHD
* Number of fatal cases/
Number of patients
** Adjusted for sex, age at
diagnosis and season of blood
sampling
Breast Colon Lung Lymphoma
HR (95% CI)** HR (95% CI)** HR (95% CI)** HR (95% CI)**
1. Quartile
(\46 nmol/L)
1.00 reference
27/45*
1.00 reference
11/13*
1.00 reference
63/63*
1.00 reference
24/40*
2. Quartile
(46–61 nmol/L)
0.55 (0.32, 0.95)
25/62*
0.48 (0.18, 1.29)
8/12*
0.40 (0.28, 0.59)
55/62*
0.59 (0.32, 1.11)
18/34*
3. Quartile
(62–81 nmol/L)
0.41 (0.23, 0.74)
20/58*
0.61 (0.23, 1.59)
11/17*
0.34 (0.22, 0.52)
38/44*
0.46 (0.25, 0.86)
20/43*
4. Quartile
([81 nmol/L)
0.37 (0.21, 0.67)
26/86*
0.40 (0.10, 1.60)
6/10*
0.19 (0.12, 0.30)
34/41*
0.33 (0.16, 0.69)
13/28*
p for trend p\0.01 p = 0.23 p\0.01 p\0.01
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of solid tumors are seen within each stage of disease at the
time of diagnosis (although, as expected,the numberof fatal
cases is limited for patients with localized cancer). This
observationweakensthe argumentforreversecausality.Itis
noteworthy in this regard that Fang et al. recently reported
that 25-OHD levels were signiﬁcantly associated with sur-
vival from prostate cancer when serum levels were deter-
mined prior to the diagnosis of cancer [11].
Alternately, it is conceivable that higher serum levels of
serum 25-OHD are causally related to improved cancer
survival. A signiﬁcant protective effect for serum 25-OHD
on mortality from all causes has recently been reported in
the National Health and Nutrition Examination Survey, a
population-based study in the United States [27]. This
interpretation is plausible mechanistically because labora-
tory studies demonstrate pleiotropic anti-cancer effects of
vitamin D (1,25(OH)2D) on many tumor types [8–14, 17,
28]. An improvement in survival from cancer in patients
given 25-OHD has yet to be demonstrated in a randomized
trial, however.
Table 3 shows that, for all types of cancer studied,
patients with vitamin D levels in the lowest quartile
experienced the shortest survival. The strength of the
associations for the four cancer types was similar. The ‘‘cut
point’’ for vitamin D sufﬁciency optimum for non-skeletal
health is the subject of intense debate [29]. Whether
25-OHD levels below 50 nmol/L would be the best deﬁ-
nition of deﬁciency is unclear. However, our results are
comparable with those reported by Goodwin et al. [10],
who also used a cut point of 50 nmol/L.
Our study has limitations, e.g., only one measurement of
vitamin D status was obtained. Although the use of a single
measurement potentially makes the study vulnerable to
dilution effects, results of a recent population-based study
demonstrate that the intra-individual variation in a single
serum measurement of 25-OHD is low and that a single
measurement is an accurate measurement of an individ-
ual’s long-term vitamin D status [30]. Thus, any random
variation introduced by imprecision associated with single
measurement would reduce the magnitude of the hazard
ratios observed. The long storage time of the serum before
25-OHD measurement could also be a weakness. However,
the strength of the association persisted when storage time
before the analyses was included in the analyses (Table 2,
Model III).
Treatment information was not available. Secular
changes in the treatment conceivably could inﬂuence sur-
vival rates if, over the time course of this study, newer
treatments were signiﬁcantly better than older treatments
and if serum levels of 25-OHD increased over time.
However, this type of confounding would require
improvement in treatment to have occurred for all four
types of cancer under study. Survival rates, especially from
lung cancer, have not changed appreciably in Norway
(http://www.kreftregisteret.no\cin2009english). Moreover,
our analysis indicates that 25-OHD levels actually
decreased slightly by calendar year of diagnosis (i.e.,
changed in a conservative direction).
Conversely, this study is population-based and has
several other strengths. For example, the use of date of
diagnosis as the start of follow-up minimizes the possibility
that the associations observed between vitamin D status
and survival are due to reverse causality. The ability to
control for disease stage is an important advantage as it
minimizes the possibility that the apparent low survival
hazard is a result of advanced disease lowering the serum
levels of 25-OHD. Additionally, no potential selection has
been introduced as all donors in JANUS who subsequently
developed cancer and were admitted to the Norwegian
Radium hospital donated a serum sample to the JANUS
serum bank.
In conclusion, the present study demonstrates positive
associations between circulating serum levels of 25-OHD,
measured at the time of diagnosis, and length of survival
for patients with cancer of breast, colon, lung, and lym-
phoma. These ﬁndings conﬁrm previous ecologic data on
vitamin D and cancer survival in Norway and add to a
growing body of literature, indicating that serum levels of
25-OHD are positively associated with cancer survival.
Intervention studies of vitamin D administration among
cancer patients will be required to determine whether these
observations are causal.
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